Polarity of α-galactosidase A uptake by renal tubule cells

Aaron S. Stern, Mary E. Klotman, Yiannis A. Ioannou, Christopher R. Burrow, Patricia D. Wilson, Paul E. Klotman, Michael S. Lipkowitz

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Background. Congenital absence of α-galactosidase in Fabry disease leads eventually to renal failure. Fabry disease is an attractive candidate for gene therapy, but uptake mechanisms of the enzyme must be understood for it to be used in treating patients with Fabry disease. Methods. Immortalized human renal epithelial cells from three regions of the tubule were grown in culture on collagen-coated Transwell filters and were incubated with recombinant α-galactosidase protein placed at either the luminal or basolateral side of the cells. Uptake into cells was measured, and kinetic studies were performed. Blocking experiments were done with mannose 6-phosphate. Results. Uptake from the basolateral side of the filters predominated in all three cell types. Only in distal tubule cells was mannose 6-phosphate able to block uptake to any degree. The kinetic data reveal a high Km for both luminal and basolateral cell surfaces. Conclusions. These data suggest that to correct the renal phenotype in Fabry disease, high levels of the enzyme will be need to be delivered to kidney cells. This will likely best be achieved with local administration of a vector containing the transgene directly to the kidney.

Original languageEnglish
Pages (from-to)S52-S55
JournalKidney International
Issue numberSUPPL. 1
StatePublished - 2002


  • Adeno-associated virus
  • Fabry disease
  • Gene therapy


Dive into the research topics of 'Polarity of α-galactosidase A uptake by renal tubule cells'. Together they form a unique fingerprint.

Cite this